+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


CD123-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for Bispecific Antibodies

  • ID: 3940069
  • Report
  • October 2016
  • Region: Global
  • 20 Pages
  • La Merie Publishing

This pdf report contains information about Bispecific Antibodies released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for Bispecific Antibodies which is listed in the "also available" below.

Featured presentations of September 2016 include the pipeline of CD123-targeted immunotherapeutics, the profile of Swiss pharmaceutical company Neovii Pharmaceuticals and the bispecific antibody profile of AMV-564 from Amphivena Therapeutics.

The September 2016 issue of our R&D and Business Tracker service about Bispecific Antibodies covers:

- T-Cell redirecting bispecific cancer antibodies
- NK cell redirecting bispecific cancer antibodies
- Bispecific immuno-oncology antibodies
- Bispecific tumor antigens targeted cancer antibodies
- Bispecific antibodies for inflammatory & autoimmune diseases
- Bispecific antibodies for cardiometabolic, infectious, neurologic, ophthalmic or pulmonary diseases

The monthly update report about Bispecific Antibodies contains:

R&D and Technology Tracker

- Pipeline changes
- Regulatory news
- Technology validations
- Manufacturing news

Business Tracker for:

- Company updates
- Collaboration
- Licensing
- Merger & acquisitions
- Financing

Clinical Trial Tracker
Scientific Publication Tracker
Featured Bispecific Antibody Profile: AMV-564
Featured Company Profile: Neovii Pharmaceuticals
Featured Target or Technology Pipeline: CD123-Targeted Immunotherapeutics

CD123-Targeted Immunotherapeutics:

- Antibody-Drug Conjugates
- Immunotoxins
- Fc-Engineered Antibodies
- T-cell Redirecting Bispecific Antibodies
- CAR T-Cells

Information about the CD123-Targeted Immunotherapeutics pipeline is provided in a tabular format and fully referenced.


Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.

Note: Product cover images may vary from those shown